Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose in acute heart failure with iron deficiency
NCT02937454Phase 4Completed
- Sponsor
- CSL Vifor
- Start
- Apr 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial in iron deficiency anemia (IDA) comparing Ferric Carboxymaltose with Placebo (2 arms). Primary endpoint: Composite of Total Heart Failure Hospitalizations and Cardiovascular Death at 52 weeks. Started Apr 2017; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02937454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937454.